Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens

The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. The aim of this study was to investigate the prognostic role of circulating VEGF, PDGF, SDF-1, osteopontin and CEA in patients randomly assigned to three bevacizumab-based regimens. Plasma sa...

Full description

Bibliographic Details
Main Authors: Antonia Martinetti, Rosalba Miceli, Elisa Sottotetti, Maria Di Bartolomeo, Filippo de Braud, Arpine Gevorgyan, Katia Fiorella Dotti, Emilio Bajetta, Manuela Campiglio, Francesca Bianchi, Giacomo Bregni, Filippo Pietrantonio
Format: Article
Language:English
Published: MDPI AG 2014-08-01
Series:Cancers
Subjects:
bevacizumab
colorectal cancer
biomarkers
angiogenesis
VEGF
CEA
SDF-1
Online Access:http://www.mdpi.com/2072-6694/6/3/1753

Internet

http://www.mdpi.com/2072-6694/6/3/1753

Similar Items